BVT.115959 misses Phase II pain endpoint

Biovitrum (SSE:BVT) said oral BVT.115959 missed the primary endpoint of a significant mean decrease in baseline pain intensity scores vs. placebo, as measured by the Likert pain scale in a Phase II tr...